Introduction {#sec1-1}
============

Cardiovascular disease (CVD) is the main cause of death and leads to over 30% of mortality annually worldwide ([@ref1]). The general risk factors for CVD include smoking, high body mass index, hypertension, lipid metabolism disorders, and diabetes mellitus, among several other factors ([@ref2]). Emerging evidence has demonstrated that genetic and environmental factors and polymorphisms also play a crucial role in the occurrence and development of CVD ([@ref3], [@ref4]). The advancement in single-nucleotide polymorphism (SNP) and genome-wide sequencing technologies has led to an increased number of in-depth studies on the genetics of CVD, and a number of candidate genes have been identified, such as those involved in the regulation of lipid metabolism ([@ref5]), inflammatory cytokines ([@ref6]), and the renin--angiotensin--aldosterone system (RAAS) ([@ref7]).

The RAAS plays a critical role in the pathogenesis of coronary heart disease, and previous studies have determined that it is involved in the progression of hypertension and vascular and left ventricular remodeling ([@ref8]). Much accumulated evidence has indicated that the RAAS is significantly associated with the initiation and progression of coronary atherosclerosis and thrombogenesis ([@ref9]). In addition, studies involving angiotensin-converting enzyme (ACE) inhibition and angiotensin II receptor blockade have highlighted the vital role of the RAAS, and gene polymorphism of the RAAS may also affect the efficacy of drug ([@ref10]). Recently, several genetic variants in the RAAS have been found to be significantly associated with CVD risk, such as an insertion/deletion polymorphism in the ACE gene, and T175M and M235T polymorphisms in the angiotensinogen (AGT) gene ([@ref11]-[@ref13]). AGT is a crucial determinant of angiotensin II levels, which is an important component of the RAAS. Furthermore, polymorphism in the AGT gene may contribute to atherogenesis in the coronary artery and may be related to the development of CVD ([@ref14], [@ref15]). The M235T polymorphism has been most widely studied; however, several inconsistent results regarding this polymorphism and CVD risk have been reported. Raygan et al. ([@ref16]), Bonfim-Silva et al. ([@ref17]), and Isordia-Salas et al. ([@ref18]) detected positive correlations, whereas Renner et al. ([@ref19]), Ranjith et al. ([@ref20]), and Erbas et al. ([@ref21]) determined that the AGT M235T polymorphism has no significant effect on the development of CVD. Meta-analyses have been performed to resolve these discrepancies; however, these analyses have been compromised by deficiencies in the sample size, and the results have been either inconclusive or only weakly significant ([@ref16]). Some of the studies have been limited to Asian populations ([@ref22], [@ref23]), and several of the most recent studies have not been considered. The aim of the present study was to compile case--control research and updated meta-analyses to explore the association between AGT M235T polymorphism and susceptibility for CVD in a range of populations for more accurate assessment.

Methods {#sec1-2}
=======

Search strategy {#sec2-1}
---------------

A systematic search of MEDLINE, Embase, China National Knowledge Infrastructure, OVID, ScienceDirect, and WanFang databases was performed to identify epidemiological studies on M235T polymorphisms of the AGT gene and CVD that were published up to October 2018. In the literature searches, various combinations of the keywords "angiotensinogen gene," "AGT," "M235T gene," "genetic polymorphism," "variants," or "variations," "coronary heart disease," "coronary artery disease," "cardiovascular disease," "myocardial infarction," "ischemic heart disease," and "coronary stenosis" were used. Only studies published in English or Chinese were included in the study. The references of all full text papers were examined to identify additional relevant studies. Secondary searches of gray literature were not performed. All retrieved articles were organized using reference manager software (Endnote 6).

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Inclusion criteria were the following: ([@ref1]) the study evaluated AGT M235T and CVD risk, ([@ref2]) original research (case--control studies) or AGT M235T genotype frequencies were provided by case--control status, ([@ref3]) the study had sufficient data to allow the association between AGT M235T and CVD risk, ([@ref4]) the study included original data, independent of other studies, and ([@ref5]) the language of the report was in English or Chinese. Exclusion criteria were the following: ([@ref1]) overlapping data, ([@ref2]) missing information (particularly genotype distributions and studies without controls), after having not received the requested information from the corresponding author, and ([@ref3]) genome scans investigating linkages without detailed genotype frequencies between cases and controls. Two reviewers independently screened the titles and abstracts for eligibility criteria. Thereafter, the reviewers read the full text of the studies that potentially met the inclusion criteria, and the literature was reviewed to determine the final inclusion of data. For each study, the following information was recorded: first author, year of publication, geographical area, ethnicity, number of cases and controls, genotypes for cases and controls, and evidence of Hardy--Weinberg equilibrium in the controls. If the two reviewers disagreed regarding the inclusions of a study, a consensus was reached through additional review and discussion.

Data extraction {#sec2-3}
---------------

The two reviewers extracted data from each study independently, and any discrepancies were resolved. The information extracted from each article in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, including first author, year of publication, country of origin, ethnicity of patients, numbers of cases and controls, AGT genotypes, allele distribution of cases and controls, and outcome, was summarized.

###### 

Characteristics and genotype frequencies for AGT M235T polymorphism in the included studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                    Year   ID   Country   Enthic          Sample size\   Genotypes and allele distribution                                                            
                                                                 Case/Control                                                                                                
  ------------------------ ------ ---- --------- --------------- -------------- ----------------------------------- ----- ----- ----- ------ ------ ----- ----- ----- ------ ------
  Tiret et al.             1995   1    France    Caucasian       630            741                                 229   301   100   759    501    258   372   111   888    594

  Kamitani et al.          1995   2    Japan     East Asian      103            103                                 6     31    66    43     163    10    41    52    61     145

  Ko et al.                1997   3    China     East Asian      150            338                                 4     22    124   30     270    4     54    279   62     612

  Chen et al.              1998   4    China     East Asian      57             76                                  4     13    40    21     93     13    31    32    57     95

  Sheu et al.              1998   5    China     East Asian      102            145                                 1     26    75    28     176    1     37    107   39     251

  Pastinen et al.          1998   6    Finland   Caucasian       122            122                                 48    66    37    162    140    53    64    34    170    132

  Frossard et al.          1998   7    UAE       Caucasian       40             61                                  14    18    8     46     34     16    26    19    58     64

  Gardemann et al.         1999   8    Germany   Caucasian       1058           511                                 319   582   157   1220   896    385   585   222   1355   1029

  Winkelmann et al.        1999   9    Germany   Caucasian       122            92                                  38    54    30    130    114    28    53    11    109    75

  Batalla et al.           2000   10   Spain     Caucasian       220            200                                 69    99    52    237    203    64    96    40    224    176

  Fomicheva et al.         2000   11   Russia    Caucasian       198            152                                 63    85    50    211    185    43    75    34    161    143

  Olivieri et al.          2001   12   Italy     Caucasian       247            245                                 63    124   60    250    244    54    76    27    184    130

  Xie et al.               2001   13   China     East Asian      106            86                                  8     29    69    45     167    11    30    45    52     120

  Fernández-Arcás et al.   2001   14   Spain     Caucasian       212            180                                 59    121   32    239    185    34    97    49    165    195

  Ermis et al.             2002   15   Turkey    Miscellaneous   102            114                                 32    48    22    112    92     39    59    16    137    91

  Hooper et al.            2002   16   USA       Miscellaneous   110            185                                 4     29    67    37     163    2     31    67    35     165

  Zhu et al.               2002   17   China     East Asian      41             116                                 2     7     32    11     71     18    47    51    83     149

  Zhu et al.               2002   18   China     East Asian      118            106                                 14    48    56    76     160    10    42    54    62     150

  Bis et al.               2003   19   USA       Caucasian       208            717                                 71    98    39    240    176    215   349   153   779    655

  Gu et al.                2003   20   China     East Asian      129            90                                  12    31    86    55     203    7     30    53    44     136

  Ranjith et al.           2004   21   India     Miscellaneous   195            300                                 24    80    91    128    262    29    127   144   185    415

  Zhu et al.               2004   22   China     East Asian      192            98                                  12    75    105   99     285    8     36    54    52     144

  Li et al.                2004   23   China     East Asian      120            80                                  11    60    49    82     158    14    41    25    69     91

  Tobin et al.             2004   24   England   Caucasian       547            505                                 212   252   83    676    418    197   226   82    620    390

  Ren et al.               2005   25   China     East Asian      100            70                                  2     10    35    14     80     13    26    31    52     88

  Araujo et al.            2005   26   Brazil    Caucasian       110            104                                 46    52    12    144    76     43    51    10    137    71

  Renner et al.            2005   27   Austria   Caucasian       1370           733                                 NA    NA    NA    1537   1203   NA    NA    NA    832    634

  Liang et al.             2006   28   China     East Asian      133            154                                 2     30    101   34     232    10    60    84    80     228

  Tsai et al.              2007   29   China     East Asian      735            519                                 15    195   525   225    1245   5     111   403   121    917

  Niu et al.               2008   30   China     East Asian      105            110                                 8     32    65    48     162    9     47    54    65     155

  Zhu et al.               2010   31   China     East Asian      151            127                                 9     27    115   45     257    20    51    56    91     163

  Peng et al.              2011   32   China     East Asian      196            200                                 14    54    128   82     155    18    86    96    122    278

  Konopka et al.           2011   33   Poland    Caucasian       100            95                                  30    46    24    106    94     22    44    29    88     102

  Mehri et al.             2011   34   Tunisia   Miscellaneous   123            144                                 29    53    41    111    135    53    61    30    167    121

  Raygan et al.            2016   35   Iran      Miscellaneous   155            185                                 42    79    34    163    147    71    85    29    227    143

  Bonfim-Silva et al.      2016   36   Brazil    Miscellaneous   153            113                                 23    69    61    115    191    13    63    37    89     137

                                                 Caucasian       306            142                                 73    145   88    291    321    34    68    40    136    148

  Erbas et al.             2017   37   Turkey    Miscellaneous   117            106                                 11    104   2     126    108    16    85    5     117    95

  Isordia-Salas et al.     2018   38   Mexico    Miscellaneous   242            242                                 138   98    6     374    110    170   62    10    402    82
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA - not available

###### 

Baseline characteristics of the included studies

  Study                    Enthic   Outcome   Genotyping-methods   Age          Gender (M/F)   HWE                  
  ------------------------ -------- --------- -------------------- ------------ -------------- ---------- --------- ----
  Tiret et al.             C        MI        PCR                  53.0±0.3     54.0±0.3       630/0      741/0     Y
  Kamitani et al.          EA       MI        PCR                  52±1         54±1           103/0      103/0     Y
  Ko et al.                EA       MI        PCR                  61.5±0.6     56.0±0.6       NR         181/157   Y
  Chen et al.              EA       MI        PCR                  67.7±8.5     65.7±8.2       50/7       69/7      Y
  Sheu et al.              EA       CAD       PCR                  NR           NR             102/0      145/0     Y
  Pastinen et al.          C        MI        PCR                  57.7±4.9     57.7±4.9       122/0      122/0     Y
  Frossard et al.          C        MI        PCR                  55.0±11.3    53.7±14.0      25/15      31/30     Y
  Gardemann et al.         C        MI        PCR                  62.2±9.5     58.5±10.6      1058/0     511/0     Y
  Winkelmann et al.        C        MI        PCR                  55.7±9.6     55.7±9.6       122/0      92/0      Y
  Batalla et al.           C        MI        PCR                  43±5         42±6           220/0      200/0     Y
  Fomicheva et al.         C        MI        PCR                  67 (55-85)   11 (6-17)      198/0      152/0     Y
  Olivieri et al.          C        MI        PCR                  57.7±12.8    59.6±9.5       160/85     221/26    Y
  Xie et al.               EA       CAD       PCR                  61.4±9.5     52.8±8.7       82/24      54/32     Y
  Fernández-Arcás et al.   C        MI        PCR                  54±13        56±15          212/0      180/0     Y
  Ermis et al.             M        MI        PCR                  42.1±11.8    40.3±12.8      NR         NR        Y
  Hooper et al.            M        MI        PCR                  NR           NR             NR         NR        Y
  Zhu et al.               EA       MI        PCR                  59.6±10.4    56.6±10.4      27/14      67/49     Y
  Zhu et al.               EA       CAD       PCR                  NR           NR             NR         NR        Y
  Bis et al.               C        MI        PCR                  63.6         64.4           128/80     371/346   Y
  Gu et al.                EA       CAD       PCR                  65.8±9.2     65.3±9.8       81/48      54/36     Y
  Ranjith et al.           M        MI        PCR                  18-45        18-45          NR         NR        Y
  Zhu et al.               EA       CAD       PCR                  NR           NR             NR         NR        Y
  Li et al.                EA       CAD       PCR                  61.5±11.8    59.3±10.5      80/40      47/33     Y
  Tobin et al.             C        MI        PCR                  61.9±9.2     58.6±10.7      372/175    313/192   Y
  Ren et al.               EA       CAD       PCR                  60.0±9.8     57.9±11.6      71/29      38/32     Y
  Arauji et al.            C        MI        PCR                  \>18         \>18           73/37      44/60     Y
  Renner et al.            C        MI        PCR                  63.1±10.4    58.4±12.1      1081/289   378/355   NR
  Liang et al.             EA       CAD       PCR                  64±8         63±8           100/33     116/38    Y
  Tsai et al.              EA       CAD       PCR                  63.8±11.4    58.6±13.1      531/204    269/250   Y
  Niu et al.               EA       CAD       PCR                  59±7         57±9           69/36      71/39     Y
  Zhu et al.               EA       CAD       PCR                  59.7±11.3    58.1±10.8      96/55      71/56     Y
  Peng et al.              EA       CAD       PCR                  70.0±8.3     69.0±6.4       128/68     132/68    Y
  Konopka et al.           C        MI        PCR                  57±10        38±11          79/21      76/19     Y
  Mehri et al.             M        MI        PCR                  62.3±11.8    60.4±10.3      71/52      83/61     Y
  Raygan et al.            M        MI        PCR                  62.4±3.2     61.7±4.3       102/53     127/58    Y
  Bonfim-Silva et al.      M        CAD       PCR                  55.7±7.9     51.8±8.4       99/54      49/64     Y
                           C        CAD       PCR                  55.7±6.7     53.0±7.7       204/102    65/77     Y
  Erbas et al.             M        CAD       PCR                  50.2±12.3    41.4±11.3      55/62      14/92     Y
  Isordia-Salas et al.     M        MI        PCR                  41.0±5.3     39.7±5.0       191/51     192/50    Y

C - Caucasian; EA - East Asian; M - Miscellaneous; MI - myocardial infarction; CAD - coronary artery disease; PCR - polymerase chain reaction; NR - no reported; HWE - Hardy-Weinberg equilibrium; Y - yes

Statistical analysis {#sec2-4}
--------------------

Data analysis was conducted using STATA 12.0 software (StataCorp, College Station, TX, USA). The association between AGT M235T polymorphism and CVD susceptibility was assessed in the following genetic models: T versus M (allelic), TT versus MM (co-dominant), MT versus MM (co-dominant), MT+TT versus MM (dominant), and MT+MM versus TT (recessive). Inter-study heterogeneity was tested using Q-statistics. The Mantel--Haenszel method for fixed effects and the DerSimonian and Laird method for random effects were used to estimate pooled effects ([@ref24]). The fixed effects method was used if the result of the Q test was not significant. Otherwise, the pooled odds ratio (OR) and 95% confidence interval (CI), assuming a random effects model, were calculated. Fixed effects assume that genetic factors have similar effects on CVD susceptibility across all studies, and that the observed variations among studies are caused by chance alone ([@ref25]). The random effects model assumes that different studies may have substantial diversity and assesses both intra- and inter-study variations ([@ref26]). A recently developed measure, I^2^, was used to quantify the inconsistency among the studies' results for values of ≥50%, with large heterogeneity among values of ≥75% ([@ref27]). Data are expressed as OR with 95% CI and two-tailed p-values. A p-value \<0.05 was considered statistically significant. Assessment of publication bias was conducted both visually by using a funnel plot and statistically via Begg's funnel plots and Egger's bias test, which measures the degree of funnel plot asymmetry ([@ref28], [@ref29]). The Begg's adjusted rank correlation test was used to assess the correlation between test accuracy estimates and their variances. The deviation of Spearman's rho values from zero provides an estimate of funnel plot asymmetry, where positive values indicate a trend toward higher levels of test accuracy in studies with smaller sample sizes. The Egger's bias test detects funnel plot asymmetry by determining whether the intercept deviates significantly from zero in a regression of the standardized effect estimates against their precision. Meta-regression analysis was applied to evaluate the heterogeneity of the studies.

Results {#sec1-3}
=======

Search results and characteristics of included studies {#sec2-5}
------------------------------------------------------

Initially, 427 potentially relevant articles were obtained; however, after screening the abstracts, most were determined to be irrelevant to our analysis. Of the remaining 51 articles, 13 articles were removed because of an insufficient number of cases or unusable data. Eventually, 23 studies in English ([@ref12]-[@ref21], [@ref30]-[@ref42]) and 15 in Chinese ([@ref43]-[@ref57]), including 39 comparisons of the AGT M235T polymorphism that all adopted the observational study design, satisfied the eligibility criteria ([Fig. 1](#F1){ref-type="fig"}). A total of 39 comparisons from the 38 studies of the AGT M235T polymorphism were included in this updated meta-analysis.

![Flow of studies for meta-analysis](AJC-21-222-g001){#F1}

The relevant studies included 9225 cases and 8406 controls (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Reference to the "overall population" indicates meta-analysis without ethnic subdivisions. Ethnicity-specific meta-analysis was categorized by Caucasian, East Asian, and other races (miscellaneous subgroup).

Association of the AGT M235T polymorphism with CVD risk in the overall population {#sec2-6}
---------------------------------------------------------------------------------

As shown in [Figure 2](#F2){ref-type="fig"}, significant heterogeneity among studies was observed for the overall population (P~h~\<0.10 or I^2^≥50%). Using the random effect models, M235T was found to be associated with an increased risk of CVD in the allelic (T vs. M: OR=1.16, 95% CI=1.05--1.27, p\<0.001) and recessive (TT vs. MT+MM: OR=1.14, 95% CI=1.06--1.23, p\<0.001) models.

![Forest plots of the association between AGT M235T polymorphism and CVD risk. (a) Allelic model, (b) homozygote model, (c) heterozygote model, (d) dominant model, and (e) recessive model](AJC-21-222-g002){#F2}

Association of the M235T polymorphism of the AGT gene with CVD risk in subgroups analysis {#sec2-7}
-----------------------------------------------------------------------------------------

When analyses were subdivided according to ethnicity, no associations were noted for Caucasians using any of the five genetic models. However, for the East Asian subgroup, M235T was significantly associated with CVD risk in allelic (T vs. M: OR=1.46, 95% CI=1.13--1.90, p\<0.001), homozygous (TT vs. MM: OR=1.78, 95% CI=1.18--2.67, p=0.01), dominant (MT+TT vs. MM: OR=1.47, 95% CI=1.05--2.04, p=0.02), and recessive (TT vs. MT+MM: OR=1.68, 95% CI=1.25--2.27, p\<0.001) models. In miscellaneous populations, a significant association between M235T and CVD risk was observed in the allelic model (T vs. M: OR=1.21, 95% CI=1.07--1.36, p\<0.001), but no association was observed in the other four genetic models. In subgroup analysis, neither moderate nor large heterogeneity was observed among Caucasians, but true heterogeneity was noted among East Asians (T vs. M: P~h~\<0.10, I^2^=83% and TT vs. MT+MM: P~h~\<0.10, I^2^=81%) and miscellaneous populations (MT vs. MM: P~h~=0.05, I^2^=51.1%) ([Table 3](#T3){ref-type="table"}).

###### 

Overall and subgroup meta-analysis of the association between AGT M235T polymorphism and risk of cardiovascular disease

  Categories                     n    T vs. M                    TT vs. MM   MT vs. MM   MT+TT vs. MM       TT vs. MM+MT                                                                                                                                               
  ------------------------------ ---- -------------------------- ----------- ----------- ------------------ -------------- ----------- -------------------------- ------ ----------- ------------------ ----------- ----------- -------------------------- ----------- -----------
  Overall                        22   1.16 (1.05-1.27)           **0.003**   73.3/0.00   1.20 (1.00-1.45)   0.05           56.5/0.00   1.06 (fixed) (0.97-1.15)   0.20   11.7/0.27   1.12 (0.99-1.26)   0.085       42.0/0.00   1.14 (1.06-1.23)           **0.003**   73.3/0.00
  **Subgroup (by population)**                                                                                                                                                                                                                                         
  Caucasian                           0.99 (fixed) (0.93-1.04)   0.584       34.1/0.10   0.95 (0.79-1.16)   0.63           43.4/0.04   1.00 (fixed) (0.91-1.11)   0.94   00.0/0.54   0.99 (0.89-1.09)   0.761       05.0/0.40   0.97 (0.82-1.16)           0.743       50.1/0.02
  East Asian                          1.46 (1.13-1.90)           **0.004**   83.0/0.00   1.78 (1.18-2.67)   **0.01**       53.8/0.01   1.05 (fixed) (0.80-1.38)   0.73   00.0/0.84   1.47 (1.05-2.04)   **0.023**   34.2/0.09   1.68 (1.25-2.27)           **0.001**   81.0/0.00
  Miscellaneous                       1.21 (fixed) (1.07-1.36)   **0.002**   40.8/0.11   1.22 (0.81-1.84)   0.33           45.0/0.08   1.23 (0.90-1.70)           0.20   51.1/0.05   1.31 (0.98-1.75)   0.065       45.5/0.08   1.20 (fixed) (0.98-1.46)   0.082       32.8/0.17

n- study numbers, OR- odds ratio, CI- confidence interval, bold values represent statistically significant findings, P~h~ - P heterogeneity (P\<0.1 was considered as a significant difference), fixed - the fixed effects model

Publication bias and sensitivity analysis {#sec2-8}
-----------------------------------------

Publication bias was not detected in the analyses of the homozygote, heterozygote, or dominant models (p\>0.05, for all). However, publication bias was noted in the analyses of the associations between M235T polymorphisms and CVD risk (allelic model: P~Egger~=0.01, P~Begg~=0.02 and recessive model: P~Egger~=0.01) ([Table 4](#T4){ref-type="table"}). Sensitivity analyses showed that the present meta-analysis was relatively stable and credible ([Fig. 3](#F3){ref-type="fig"}).

###### 

Publication bias assessment of this meta-analysis

  Genetic model        Egger's test t-value   *P*    Begg's test t-value   *P*
  -------------------- ---------------------- ------ --------------------- ------
  Allelic model        2.70                   0.01   2.42                  0.02
  Homozygote model     1.84                   0.07   1.28                  0.20
  Heterozygote model   -0.2                   0.85   0.10                  0.92
  Dominant model       1.18                   0.24   0.85                  0.39
  Recessive model      2.83                   0.01   1.91                  0.06

*P*\<0.05 was considered as a significant difference

![Sensitivity analyses of the association between AGT M235T polymorphism and CVD risk. (a) Allelic model, (b) homozygote model, (c) heterozygote model, (d) dominant model, and (e) recessive model](AJC-21-222-g003){#F3}

Meta-regression {#sec2-9}
---------------

A meta-regression analysis for several potential sources of heterogeneity, including published year, sample size, age, gender, outcome, and ethnic background, was performed. Single covariates were added in the allelic, homozygote, dominant, and recessive models. The results suggest that the East Asian population (allelic model: p=0.006, homozygote model: p=0.010, dominant model: p=0.022, and recessive model: p=0.005) and study size (homozygote model: p=0.042 and recessive model: p=0.010) contributed to the observed heterogeneity across all studies of the association between AGT M235T polymorphisms and CVD susceptibility.

Discussion {#sec1-4}
==========

The AGT gene (on chromosome 1q42--43) comprises five exons and four introns spanning 12 kb, with the M235T polymorphism in exon 2. The M235T variant has been demonstrated to alter plasma AGT levels ([@ref58], [@ref59]), with elevated levels of serum AGT for patients carrying the T allele ([@ref60]). Furthermore, a positive correlation exists between AGT M235T genotype and plasma AGT levels in survivors of myocardial infarction (MI) ([@ref14]). Elevation circulating AGT levels are associated with an increase in the concentration of angiotensin II, which activates cardiomyocyte hypertrophy and fibroblast proliferation by stimulation the AT1 receptor ([@ref61], [@ref62]). In addition, angiotensin II stimulates vascular apoptosis and may promote the retention of low-density lipoprotein in the coronary arteries, oxidize, and be assimilated by phagocytes, ultimately contributing to the dysfunction of the vascular endothelium and myocardial ischemia and rupture of atherosclerotic plaque ([@ref63]-[@ref65]). These processes all play critical roles in promoting the pathological development of CVD.

In previous studies, the distribution of the AGT M235T variant has been shown to differ significantly among various populations. Katsuya et al. ([@ref66]) demonstrated that homozygous AGT T235 is an independent risk factor, which carries a two-fold increased risk of CVD. In contrast, Tiret et al. ([@ref31]) suggested that the AGT genetic polymorphism can lead to predisposition to hypertension, with no relationship to CVD. Renjith et al. ([@ref20]) and Renner et al. ([@ref19]) reported similar results showing that AGT genotypes are neither related to CVD nor high blood pressure. Batalla et al. ([@ref12]) and Bonfim-Silva et al. ([@ref17]) provided evidence of the synergistic effect between AGT polymorphism and CVD, suggesting that M235T polymorphism is significantly correlated with MI and hypertension. Recently, Raygan et al. ([@ref16]) suggested that M235T polymorphism in Asians can be a useful biomarker for screening of individuals susceptible to MI. Given the disparity of the results, we sought to provide an updated meta-analysis to resolve the discrepancies among studies.

Our results clearly demonstrate a difference in the association of M235T polymorphism among Asians and Caucasians, suggesting that there is heterogeneity based on ethnicity. Our results suggest that the T allele is a genetic risk factor for CVD in Asians, as well as in the miscellaneous population. Previous meta-analyses based on Chinese populations have shown similar positive results ([@ref22], [@ref23]). Although two recent meta-analyses ([@ref16], [@ref67]) reported an association between the AGT M235T variant and MI, they did not include recently published studies, and the literature sample size was smaller than the current analysis. Thus, an update of previous meta-analyses that included diverse populations was warranted. Our results include the largest sample size to date and provide an ethnicity-based explanation for different results among studies. The association of AGT M235T with stroke was not addressed in the present study but would be an important topic for consideration in future studies to maintain a relatively narrow focus.

The following potential factors may account for differences observed among the various ethnic groups: ([@ref1]) population diversity ([@ref68]), ([@ref2]) different habits among populations ([@ref69]), and ([@ref3]) environmental factors leading to differences in susceptibility to CVD ([@ref70]). Furthermore, we speculate that the non-significant association among Caucasians may be due to the relatively low frequency of the TT genotype in this population. Moreover, owing to the limited number of these studies, the miscellaneous ethnic subgroups were not analyzed further. Therefore, more studies with a larger sample size may reveal factors that influence differences in the association of AGT M235T and CVD, especially among Caucasians and other ethnic populations. The association between AGT M235T and CVD among Asians is evident.

The heterogeneity of associations across all included studies should be noted as it may potentially affect the strength of the present study. Thus, the random effects model was used, and our analysis was based on different ethnic subgroups. Ethnic background and sample size were found to be factors of heterogeneity. However, heterogeneity was still high within the East Asian subgroup. The heterogeneity of results among those included in these studies may be explained by the quality of the included studies, classification of CVD, and sampling criteria. The heterogeneity of genetic effects among individual studies may also be caused by the existence of genetic and environmental or genetic interactions.

Study limitations {#sec2-10}
-----------------

The primary limitations of our meta-analysis include: ([@ref1]) significant publication bias in the allelic and recessive models, ([@ref2]) insufficient genotyping data of AGT M235T in miscellaneous races, which limited the ability to draw conclusions regarding this population, and ([@ref3]) potential heterogeneity of clinical variables, such as the general condition of subjects, their medical history, medication compliance, complications of CVD, and other factors.

Conclusion {#sec1-5}
==========

The genetic polymorphism of AGT M235T is associated with a critical risk of CVD in East Asian populations, with no detectable association in Caucasian populations. However, further studies with multiple ethnicities and rigorous designs should be performed to confirm these conclusions.
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